mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Antidepressant Action of Ketamine: In contrast to the weeks or months of treatment required for standard antidepressant medication, ketamine administration produces an antidepressant response within 4 to 6 hours in depressed patients. What lies behind the rapid actions of ketamine? Li et al. (p. 959 ; see the Perspective by Cryan and O'Leary ) found that ketamine administration resulted in fast activation of mammalian target of rapamycin (mTOR) signaling and increased levels of synaptic proteins in the rat prefrontal cortex. Ketamine rapidly increased the density and function of the dendritic spines of layer V pyramidal neurons in the prefrontal cortex. Thus, the behavioral actions of ketamine in models of depression and antidepressant response are dependent on mTOR signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have suggested that ketamine can increase the synthesis of synaptic proteins through BDNF signaling dependent on the activate protein kinase B (Akt) and mammalian target of rapamycin complex 1 (mTORC1) signaling cascades. 378 , 379”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Esmethadone can also alleviate neural dysfunction linked to symptoms of depression by boosting the synapse and spine density and restoring spinogenesis, in addition to correcting depressive-like behaviors in animal models of depression. 378 , 477”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine rapidly and transiently increases glutamate transmission in the PFC, possibly via inhibition of tonically active GABAergic inter-neurons, and the resulting burst of glutamate is thought to underlie ketamine induction of synapto-genesis (6, 7).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single dose of ketamine increases BDNF release and stimulates mTORC1 signaling, which leads to increased levels of synaptic proteins (i.e., GluR1, PSD95, and synapsin 1) and increased number and function of synapses in the PFC 4,22,35 .”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [35]
Experimental — accuracy not yet measured
42 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
mTOR signaling: At the crossroads of plasticity, memory and disease
Hoeffer, C. A., & Klann, E. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2009.11.003 · Cited by 1,128
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Preskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 518
Functional neuroimaging studies of depression: The anatomy of melancholia
Drevets, W. C. (1998) · Annual Review of Medicine · doi:10.1146/annurev.med.49.1.341 · Cited by 500
Liu, R.-J., & Aghajanian, G. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706679105 · Cited by 346
Self-citation
Cited by
Items 701–800 of 1,062
Small-Molecule Inhibitors at the PSD-95/nNOS Interface have Antidepressant-Like Properties in Mice
Doucet, M. V., Levine, H., Dev, K. K., & Harkin, A. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.57 · Cited by 74
“Treatment with a single dose of ketamine increased the number and function of mature spines in the prefrontal cortex of rats 24 h following drug administration (Li et al, 2010) and reversed the reduction in spine density caused by chronic unpredictable stress (Li et al, 2011).”
Backgroundde Bartolomeis, A., Sarappa, C., Buonaguro, E. F., Marmo, F., Eramo, A., Tomasetti, C., & Iasevoli, F. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.06.010 · Cited by 72
“, 2007) and increased Arc and PSD-95 protein levels in rat prefrontal cortex (Li et al., 2010).”
BackgroundDiscovery of NV-5138, the first selective Brain mTORC1 activator
Sengupta, S., Giaime, E., Narayan, S., Hahm, S., Howell, J., O’Neill, D., Vlasuk, G. P., & Saiah, E. (2019) · Scientific Reports · doi:10.1038/s41598-019-40693-5 · Cited by 72
Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review
Salahudeen, M. S., Wright, C. M., & Peterson, G. M. (2020) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620937899 · Cited by 72
Gruner (2017) · doi:10.1016/j.neuroscience.2016.11.029 · Cited by 72
Is There Anything Really Novel on the Antidepressant Horizon?
Murrough, J. W., & Charney, D. S. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0321-8 · Cited by 69
Rapid-acting antidepressants and the circadian clock
Sato, S., Bunney, B. G., Mendoza-Viveros, L., Bunney, W. E., Borrelli, E., Sassone‐Corsi, P., & Orozco-Solís, R. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01241-w · Cited by 72
“In rodents, ketamine was shown to reduce depressive-like behavior starting 30min postinjection (paralleling changes in BDNF and mTOR levels in the hippocampus) with antidepressant effects lasting for several days [81, 83].”
BackgroundMarsden, W. N. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.06.021 · Cited by 73
Molecular Neurobiology and Promising New Treatment in Depression
Jeon, S. R., & Kim, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030381 · Cited by 73
“These results suggest that mTOR plays a major role in antidepressant effects through ketamine [96].”
BackgroundWang, H., Huang, B., Wang, W., Li, J., Chen, Y., Flynn, T., Zhao, M., Zhou, Z., Lin, X., Zhang, Y., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.09.049 · Cited by 72
Prognosis and Improved Outcomes in Major Depression: A Review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2020) · Focus · doi:10.1176/appi.focus.18205 · Cited by 62
Stuart, S. A., Butler, P., Munafò, M. R., Nutt, D. J., & Robinson, E. S. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.59 · Cited by 71
Ketamine and its metabolites: Potential as novel treatments for depression
Zhang, K., Yao, Y., & Hashimoto, K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109305 · Cited by 72
Ru, Q., Lu, Y., Saifullah, A. B., Blanco, F. A., Yao, C., Cata, J. P., Li, D., Tolias, K. F., & Li, L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158545 · Cited by 73
“Genotyping of signaling have been implicated in the antidepressant-like effects of ketamine in models of stress-induced depression (59, 60), but whether they also contribute to ketamine’s antidepressant-like effects in chronic pain–induced depression and how they interact with Tiam1-mediated…”
Ehninger, D. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.015 · Cited by 71
Prospects for mTOR-mediated functional repair after central nervous system trauma
Berry, M., Ahmed, Z., Morgan-Warren, P. J., Fulton, D. J., & Logan, A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.10.002 · Cited by 71
“, 2014), synaptic protein production, synaptic plasticity (Hoeffer and Klann, 2009) and the morphology and possibly the density of dendritic spines (Lai et al., 2006; Li et al., 2010; Haws et al., 2014; Di Polo, 2015).”
BackgroundNMDA antagonist treatment of depression
Williams, N., & Schatzberg, A. F. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.11.001 · Cited by 72
Agmatine produces antidepressant-like effects by activating AMPA receptors and mTOR signaling
Neis, V. B., Moretti, M., Bettio, L. E. B., Ribeiro, C. M., da Rosa, P. B., Gonçalves, F. M., Lopes, M. W., Leal, R. B., & Rodrigues, A. L. S. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.03.009 · Cited by 71
“Although an enhanced phosphorylation of GluA1 has been detected following fluoxetine, imipramine, and ketamine treatment, it seems that only ketamine is able to cause a rapid increase in postsynaptic AMPAR expression (Cai et al., 2013; Li et al., 2010).”
BackgroundInfluentialInvolvement of PI3K/Akt/GSK-3β and mTOR in the antidepressant-like effect of atorvastatin in mice
Ludka, F. K., Constantino, L. C., Dal-Cim, T. A., Binder, L. B., Zomkowski, A. D. E., Rodrigues, A. L. S., & Tasca, C. I. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.07.004 · Cited by 71
“…by α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors stimulation and protein kinase B (Akt)/ glycogen synthase kinase-3 beta (GSK-3β) and mammalian target of rapamycin (mTOR) pathway modulation (Li et al., 2010) that are involved in protein synthesis (Duman et al., 2012).”
BackgroundInfluentialMood‐related central and peripheral clocks
Ketchesin, K. D., Becker‐Krail, D., & McClung, C. A. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14253 · Cited by 61
“The longer lasting antidepressant effects of ketamine (up to 2 weeks) involve activation of mTOR signaling pathways, brain- derived neurotrophic factor (BDNF) release, and changes in dendritic spines (Autry et al., 2011; Li et al., 2010).”
BackgroundAffective Immunology: The Crosstalk Between Microglia and Astrocytes Plays Key Role?
Yang, L., Zhou, Y., Jia, H., Qi, Y., Tu, S., & Shao, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01818 · Cited by 62
“On the other hand, the anti-depressive effect of ketamine should ascribe to a reversal of another downstream process of AAMC-triggered neuroinflammation, the synaptic remolding in mood disorders (63, 123, 146).”
BackgroundKetamine Influences CLOCK:BMAL1 Function Leading to Altered Circadian Gene Expression
Bellet, M. M., Vawter, M. P., Bunney, B. G., Bunney, W. E., & Sassone-Corsi, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023982 · Cited by 70
Cannabinoid Modulation of the Stressed Hippocampus
Scarante, F. F., Vila-Verde, C., Lopes, V. D., Ferreira‐Junior, N. C., Guimarães, F. S., & Campos, A. C. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00411 · Cited by 70
“…of cannabinoid drugs in stress-related neuroplasticity, the mechanistic (or mammalian) target of rapamycin (mTOR) protein has been implicated in synaptogenesis, proliferative processes, and synaptic strength modulation (Li et al., 2010; Ma et al., 2010; Romine et al., 2015; Liang et al., 2016).”
BackgroundChávez-Castillo, M., Núñez, V., Nava, M., Ortega, Á., Rojas, M., Bermúdez, V., & Rojas, J. (2019) · Advances in Pharmacological Sciences · doi:10.1155/2019/7943481 · Cited by 72
“Although both appear to have significant antidepressant effects in the short term, neither appear to be as long-acting as ketamine [21, 66].”
BackgroundAn update on NMDA antagonists in depression
Pochwat, B., Nowak, G., & Szewczyk, B. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1643237 · Cited by 70
“Ketamine and a few other NMDAR antagonists induce the activation of the mTOR kinase [8,13,18,21].”
BackgroundInfluentialGlutamatergic Modulators for Major Depression from Theory to Clinical Use
McIntyre, R. S., & Jain, R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01114-y · Cited by 69
“…of eukaryotic elongation factor 2 (eEF2), allowing for protein translation [45]. mTOR activation thus increases the expression of synaptic proteins vital for the formation, maturation, and function of synaptic spines and can lead to increases in the density of dendritic spines [44–47].”
BackgroundThomas, R. K., Baker, G., Lind, J., & Dursun, S. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118793104 · Cited by 69
Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression
Wang, Y., Wang, X., Feng, S., Chen, N., Wang, Z., & Zhang, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105761 · Cited by 69
mTOR signaling as a molecular target for the alleviation of Alzheimer's disease pathogenesis
Rapaka, D., Bitra, V. R., Challa, S. R., & Adiukwu, P. C. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105311 · Cited by 70
Lima‐Ojeda, J. M., Vogt, M. A., Pfeiffer, N., Dormann, C., Köhr, G., Sprengel, R., Gass, P., & Inta, D. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.04.017 · Cited by 69
Cunha, M. P., Budni, J., Ludka, F. K., Pazini, F. L., Rosa, J. M., Oliveira‐Giacomelli, Á., Lopes, M. W., Tasca, C. I., Leal, R. B., & Rodrigues, A. L. S. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9192-4 · Cited by 70
Robinson, E. S. J. (2018) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2017.0036 · Cited by 69
Uddin, M. S., Rahman, M. A., Kabir, M. T., Behl, T., Mathew, B., Perveen, A., Barreto, G. E., Bin‐Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · IUBMB Life · doi:10.1002/iub.2324 · Cited by 68
Retinal ganglion cell dendrite pathology and synapse loss
Agostinone, J., & Di Polo, A. (2015) · Progress in Brain Research · doi:10.1016/bs.pbr.2015.04.012 · Cited by 68
Kaut, O., Schmitt, I., Hofmann, A., Hoffmann, P., Schlaepfer, T. E., Wüllner, U., & Hurlemann, R. (2015) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0572-y · Cited by 68
Engers, J. L., Rodriguez, A. L., Konkol, L. C., Morrison, R. D., Thompson, A. D., Byers, F. W., Blobaum, A. L., Chang, S., Venable, D. F., Loch, M. T., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01005 · Cited by 68
Antidepressant mechanism of ketamine: perspective from preclinical studies
Scheuing, L., Chiu, C.-T., Liao, H.-M., & Chuang, D.-M. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00249 · Cited by 65
Bambico, F. R., & Belzung, C. (2012) · Current topics in behavioral neurosciences · doi:10.1007/7854_2012_234 · Cited by 68
“is a naturally slower process (Hajszan et al. 2005; Li et al. 2010; Autry et al. 2011) (Fig.”
BackgroundInfluentialKim, S., Lee, H., Kim, H., Bang, E., Lee, S., Lee, D., Woo, D., Choi, C., Hong, K. S., Lee, C., et al. (2011) · NMR in Biomedicine · doi:10.1002/nbm.1681 · Cited by 63
Iijima, M., Fukumoto, K., & Chaki, S. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.08.016 · Cited by 68
Chiu, C.-T., Scheuing, L., Liu, G., Liao, H.-M., Linares, G. R., Lin, D., & Chuang, D.-M. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu102 · Cited by 66
“Similar to the observations described above, we found that only pretreatment with 600 mg/L of lithium plus subsequent challenge with 2.5 mg/kg of ketamine significantly increased phosphorylation levels of TrkB (a BDNF receptor; 123.02 ± 6.49%, P < .05), Akt (184.18 ± 8.57%, P < .01), ERK (156.59 ± 14.37%, P < .05), an…”
BackgroundInfluentialLinking Mitochondria to Synapses: New Insights for Stress-Related Neuropsychiatric Disorders
Jeanneteau, F., & Arango-Lievano, M. (2016) · Neural Plasticity · doi:10.1155/2016/3985063 · Cited by 64
“Althoughmost antidepressants reduced metabolic functions of mitochondria, the redox functions increased in conditions that facilitate synaptic functions [77, 98].”
BackgroundAlcohol‐dependent molecular adaptations of the NMDA receptor system
Morisot, N., & Ron, D. (2017) · Genes Brain & Behavior · doi:10.1111/gbb.12363 · Cited by 68
“Furthermore, similar to the actions of ketamine and Ro25-6981 (Li et al. 2010), excessive alcohol consumption initiated the activation of the translational machinery leading to the translation of synaptic proteins including the collapsin response mediator protein 2 (CRMP-2), HOMER, PSD-95, Arc and…”
BackgroundInfluentialErburu, M., Muñoz-Cobo, I., Diaz-Perdigon, T., Mellini, P., Suzuki, T., Puerta, E., & Tordera, R. M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.01.033 · Cited by 61
“Importantly, activation of glutamate receptors in the PFC has been linked to antidepressant-like effects (Li et al., 2010; Koike et al., 2011).”
Ko, M. J., Mulia, G. E., & van Rijn, R. M. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00096 · Cited by 68
Kokane, S. S., Armant, R. J., Bolaños-Guzmán, C. A., & Perrotti, L. I. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112548 · Cited by 61
Rapid Acting Antidepressants in Chronic Stress Models: Molecular and Cellular Mechanisms
Hare, B. D., Ghosal, S., & Duman, R. S. (2017) · Chronic Stress · doi:10.1177/2470547017697317 · Cited by 67
“Conversely, there is evidence that a critical component of the therapeutic action of rapid acting antidepressants includes the induction of trophic factor signaling and subsequent synaptogenesis in the PFC.(17,18) With ketamine, an NMDA receptor antagonist, these effects occur following a transient increase in glutama…”
BackgroundInfluentialSelf-citationPiantadosi, S. C., French, B. J., Poe, M. M., Timić, T., Marković, B. D., Pabba, M., Seney, M. L., Oh, H., Orser, B. A., Savić, M. M., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00446 · Cited by 67
“…with rapid acting antidepressant effects have shown promise in preclinical studies and effectiveness in treating severely depressed individuals (Li et al., 2010; Zarate et al., 2012a,b), no existing antidepressant drug directly addresses the pathology observed in the depressed brain, providing…”
BackgroundSeo, M. K., Jeong, S., Seog, D.-H., Lee, J. A., Lee, J.-H., Lee, Y., McIntyre, R. S., Park, S. W., & Lee, J. G. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.12.089 · Cited by 60
Li, Q., Takeuchi, Y., Wang, J., Gellért, L., Barcsai, L., Pedraza, L. K., Nagy, A. J., Kozák, G., Nakai, S., Kato, S., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.04.013 · Cited by 68
Agnorelli, C., Spriggs, M. J., Godfrey, K., Sawicka, G., Bohl, B., Douglass, H. M., Fagiolini, A. M., Hashemi, P., Carhart-Harris, R. L., Nutt, D. J., et al. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106132 · Cited by 69
“Li et al. showed that the effect was mediated by mTOR (Li et al., 2010).”
Riggs, L. M., Aracava, Y., Zanos, P., Fischell, J., Albuquerque, E. X., Pereira, E. F. R., Thompson, S. M., & Gould, T. D. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0443-3 · Cited by 66
Treatment for Substance Use Disorder with Co-Occurring Mental Illness
Iqbal, M. N., Levin, C. J., & Levin, F. R. (2019) · Focus · doi:10.1176/appi.focus.20180042 · Cited by 66
Gärtner, M., Aust, S., Bajbouj, M., Fan, Y., Wingenfeld, K., Otte, C., Heuser-Collier, I., Böker, H., Hättenschwiler, J., Seifritz, E., et al. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.02.008 · Cited by 66
Pereira, V. S., Casarotto, P. C., Hiroaki-Sato, V. A., Sartim, A. G., Guimarães, F. S., & Joca, S. R. L. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.01.008 · Cited by 66
“Classical and atypical antidepressant drugs (McArthur and Borsini, 2006; Li et al., 2010) reduce the immobility time of animals exposed to FST.”
Mechanisms of Action of TMS in the Treatment of Depression
Downar, J. H., Siddiqi, S., Mitra, A., Williams, N., & Liston, C. M. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_483 · Cited by 66
Zhu, W.-L., Wang, S.-J., Liu, M.-M., Shi, H.-S., Zhang, R.-X., Liu, J.-F., Ding, Z.-B., & Lu, L. (2013) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.120228 · Cited by 62
“5 μl) from Sigma and dissolved it in saline containing 50% DMSO, as described in previous reports.(6,22) Rapamycin (50 μg/0.”
BackgroundMethodNiesters, M., & Dahan, A. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.712686 · Cited by 66
“Recent animal studies have shown that ketamine produces these antidepressant effects via NMDAR inhibition [55].”
BackgroundGasull-Camós, J., Tarrés-Gatius, M., Artigas, F., & Castañé, A. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.7 · Cited by 62
Marathe, S. V., D’almeida, P., Virmani, G., Bathini, P., & Alberi, L. A. (2018) · Journal of Experimental Neuroscience · doi:10.1177/1179069518789149 · Cited by 66
Wilson, M. A., Grillo, C. A., Fadel, J. R., & Reagan, L. P. (2015) · Neurobiology of Stress · doi:10.1016/j.ynstr.2015.06.001 · Cited by 66
“Ketamine increases the expression of synaptic proteins and the number of excitatory spines in PFC, suggesting that behavioral effects may be a consequence of changes in synaptic plasticity and synaptogenesis (Li et al., 2010, 2011).”
BackgroundAdult neuroplasticity: A new “cure” for major depression?
Albert, P. R. (2019) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.190072 · Cited by 66
5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice
Jefferson, S. J., Gregg, I., Dibbs, M., Liao, C., Wu, H., Davoudian, P. A., Woodburn, S. C., Wehrle, P. H., Sprouse, J. S., Sherwood, A. M., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01572-w · Cited by 65
“Prior studies accordingly found retraction of dendritic spines after chronic stress [33, 34] and the fast-acting antidepressant ketamine can increase spine formation [35, 36] and restore stress-induced spine loss [37, 38].”
BackgroundDrugs of abuse hijack a mesolimbic pathway that processes homeostatic need
Tan, B., Browne, C. J., Nöbauer, T., Vaziri, A., Friedman, J. M., & Nestler, E. J. (2024) · Science · doi:10.1126/science.adk6742 · Cited by 65
Catches, J. S., Xu, J., & Contractor, A. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.12.026 · Cited by 59
“Moreover, there has been a resurgence of interest in the link between glutamatergic neurotransmission and depression because glutamate receptor ligands, particularly non-competitive antagonists of NMDA receptors, have demonstrated efficacy as anti-depressants both in animal models [12–16] and human studies [17, 18].”
Ketamine for depression: evidence, challenges and promise
Zarate, C. A., & Niciu, M. J. (2015) · World Psychiatry · doi:10.1002/wps.20269 · Cited by 61
“resulting in some or all of the following: mammalian target of rapamycin (mTOR) activation (14), increased brain-derived”
BackgroundWang, Y., Gu, N., Duan, T., Kesner, P., Blaskovits, F., Liu, J., Lu, Y., Li, T., Gao, F., Harris, C. S., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.22 · Cited by 65
Strong, C. E., & Kabbaj, M. (2018) · Neurobiology of Stress · doi:10.1016/j.ynstr.2018.09.001 · Cited by 60
Protein Translation and Psychiatric Disorders
Laguesse, S., & Ron, D. (2019) · The Neuroscientist · doi:10.1177/1073858419853236 · Cited by 65
Sex differences in resilience: Experiential factors and their mechanisms
Fallon, I. P., Tanner, M. K., Greenwood, B. N., & Baratta, M. V. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14639 · Cited by 65
“The mammalian target of rapamycin (mTOR) pathway, an important player in spine formation and maturation, is necessary for ketamine-induced increases in spine formation in the mPFC and its ability to blunt stress effects on forced swim, inescapable stress and the novelty suppressed feeding test (Li et al., 2010).”
BackgroundCrocin Reverses Depression-Like Behavior in Parkinson Disease Mice via VTA-mPFC Pathway
Tang, J., Lu, L., Wang, Q., Liu, H., Xue, W., Zhou, T., Xu, L., Wang, K., Wu, D., Wei, F., et al. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01941-2 · Cited by 65
On the safety and benefits of repeated intravenous injections of ketamine for depression.
Blier, P., Zigman, D., & Blier, J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.02.039 · Cited by 64
Zhou, Z., Zhang, G., Li, X., Liu, X., Wang, N., Qiu, L., Liu, W., Zuo, Z., & Yang, J. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8798-2 · Cited by 64
Self-citationWoelfer, M., Li, M., Colic, L., Liebe, T., Di, X., Biswal, B., Murrough, J., Lessmann, V., Brigadski, T., & Walter, M. (2020) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1679391 · Cited by 64
Trehalose induced antidepressant-like effects and autophagy enhancement in mice
Kara, N. Z., Toker, L., Agam, G., Anderson, G. W., Belmaker, R. H., & Einat, H. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3119-4 · Cited by 64
Ponton, E., Turecki, G., & Nagy, C. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab082 · Cited by 65
“…to the postsynaptic TrkB receptor, activating the MAPK and PI3K signaling pathways (Huang and Reichardt 2003; Yang et al., 2015; Ho et al., 2018), leading to phosphorylation of Mek/Erk and Akt, respectively, and the phosphorylation and activation of mTOR (Li et al., 2010; Duman et al., 2016).”
GluN2A mediates ketamine-induced rapid antidepressant-like responses
Su, T., Lu, Y., Fu, C., Geng, Y., & Chen, Y. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01436-y · Cited by 64
Zhang, H., Xue, W., Wu, R., Gong, T., Tao, W., Zhou, X., Jiang, J., Zhang, Y., Zhang, N., Cui, Y., et al. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/761238 · Cited by 64
“Indeed, high dose of ketamine also failed to show rapid antidepressant effects and only appropriate dose of ketamine can activate mammalian target of rapamycin (mTOR) signaling leading to upregulation of synaptic plasticity for antidepressant responses [8].”
BackgroundMethodInfluentialKetamine: repurposing and redefining a multifaceted drug
Potter, D. E., & Choudhury, M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.08.017 · Cited by 65
Jiang, B., Wang, F., Yang, S., Fang, P., Deng, Z.-F., Xiao, J.-L., Hu, Z.-L., & Chen, J.-G. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu096 · Cited by 62
“Other brain regions, like the medial prefrontal cortex (mPFC) and nucleus accumbens (NAc), are also implicated in depression (Di Chiara et al., 1999; Krishnan et al., 2007; Li et al., 2010).”
BackgroundJiménez-Sánchez, L., Linge, R., Campa, L., Valdizán, E. M., Pazos, Á., Díaz, Á., & Adell, A. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.020 · Cited by 66
Liu, Y., Hu, C., Shen, J.-D., Wu, S., Li, Y., & Yi, L. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.12.003 · Cited by 66
McGirr, A., LeDue, J., Chan, A. W., Xie, Y., & Murphy, T. H. (2017) · Brain · doi:10.1093/brain/awx142 · Cited by 59
Antidepressant-like effects of ginsenoside Rg2 in a chronic mild stress model of depression
Ren, Y., Wang, J., Zhang, X., Wang, H., Ye, Y., Song, L., Wang, Y., Tu, M., Wang, W., Yang, L., et al. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.08.009 · Cited by 64
“Moreover, recent research has been founding more and more proteins and molecular pathways that are involved in depression, like mTOR signaling pathway, vascular endothelial growth factor (VEGF), △FosB, and so on (Warner-Schmidt and Duman, 2007; Li et al., 2010; Nestler, 2015).”
BackgroundWang, W., Liu, L., Yang, X., Gao, H., Tang, Q.-K., Yin, L.-Y., Yin, X.-Y., Hao, J.-R., Geng, D.-Q., & Gao, C. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.01.057 · Cited by 61
Metaplastic Effects of Subanesthetic Ketamine on CA1 Hippocampal Function
Izumi, Y., & Zorumski, C. F. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.08.002 · Cited by 63
“, 2010), and antagonists with selectivity for GluN2B (NR2B) subunits also show antidepressant actions (Li et al., 2010).”
InfluentialLimon, A., Mamdani, F., Hjelm, B. E., Vawter, M. P., & Sequeira, A. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.04.010 · Cited by 63
A New Rapid-Acting Antidepressant
Krystal, J. H., Charney, D. S., & Duman, R. S. (2020) · Cell · doi:10.1016/j.cell.2020.02.033 · Cited by 63
Self-citationMilak, M. S., Rashid, R., Dong, Z., Kegeles, L. S., Grunebaum, M. F., Ogden, R. T., Lin, X., Mulhern, S. T., Suckow, R. F., Cooper, T. B., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.13211 · Cited by 63
Ren, L., & Chen, G. (2017) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2017.03.042 · Cited by 63
Lavender, E., Hirasawa-Fujita, M., & Domino, E. F. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112631 · Cited by 58
Wang, J., Gao, F., Cui, S., Yang, S., Gao, F., Wang, X., & Zhu, G. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106079 · Cited by 63
Chen, T., Cheng, L., Ma, J., Yuan, J., Pi, C., Xiong, L., Chen, J., Liu, H., Tang, J., Zhong, Y., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106837 · Cited by 52
The impact of adult neurogenesis on affective functions: of mice and men
Alonso, M., Petit, A., & Lledo, P. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02504-w · Cited by 63
“This mode of action explains their rapid effectiveness although repeated administrations are required to produce long-lasting antidepressant effect (for ketamine see [117 – 119]; for psilocybin [120, 121]).”
BackgroundSzymkowicz, S. M., Finnegan, N., & Dale, R. M. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.10.015 · Cited by 61
“, 2008) and stimulates the mammalian Target of Rapamycin (mTOR; Li et al., 2010), both of which may play a part in its antidepressant effects.”
BackgroundInfluentialRomine, J., Gao, X., Xu, X., So, K., & Chen, J. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.01.003 · Cited by 63
Borroto‐Escuela, D. O., Tarakanov, A. O., Guidolin, D., Ciruela, F., Agnati, L. F., & Fuxé, K. (2011) · IUBMB Life · doi:10.1002/iub.473 · Cited by 64
“Furthermore, a highly interesting article has recently appeared demonstrating that the rapid antidepressant actions of N-methyl-D-aspartic acid (NMDA) antagonists (56) may be produced via mTOR-dependent synapse formation (57).”
Backgrounddu Jardin, K. G., Müller, H. K., Elfving, B., Dale, E., Wegener, G., & Sanchez, C. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.05.007 · Cited by 53
“Furthermore, the association between rapamycin (selective mTOR inhibitor), antidepressantlike effects, and ketamine may be ambiguous (Autry et al., 2011; Cleary et al., 2008; Li et al., 2010).”
InfluentialBath, K. G., Russo, S. J., Pleil, K. E., Wohleb, E. S., Duman, R. S., & Radley, J. J. (2017) · Neurobiology of Stress · doi:10.1016/j.ynstr.2017.05.001 · Cited by 63
“pressants promote synaptic plasticity through activation of mTORC1 signaling (Li et al., 2010; Voleti et al., 2013).”
InfluentialSelf-citationSattar, Y., Wilson, J., Khan, A., Adnan, M., Larios, D. A., Shrestha, S., Rahman, Q., Mansuri, Z., Hassan, A., Patel, N. B., et al. (2018) · Cureus · doi:10.7759/cureus.2652 · Cited by 64
Metadata
- Authors
- Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S.
- Affiliations
- Yale University (US)
- Laboratory of Molecular Psychiatry, Center for Genes and Behavior, Departments of Psychiatry and Neurobiology, Yale University School of Medicine, 34 Park Street, New Haven, CT 06508, USA.
- Corresponding author
- Duman, Ronald S.
- Venue
- Science
- Published
- 2010-08-20
- Volume
- 329
- Issue
- 5994
- Pages
- 959-964
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3116441
- OpenAlex
- W2089351762
- Cited by
- 2,881
- References
- 14
- Citations by year
- 2026: 147 · 2025: 161 · 2024: 171 · 2023: 175 · 2022: 218 · 2021: 234 · 2020: 233 · 2019: 202 · 2018: 199 · 2017: 171 · 2016: 205 · 2015: 217 · 2014: 136 · 2013: 153 · 2012: 125
- FWCI
- 96.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute of Mental Health (2P01 MH25642, MH-45481, P01MH025642, R01MH045481)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, mTOR signaling, synaptogenesis, NMDA receptor antagonists, rapid antidepressant effects, treatment-resistant depression, prefrontal cortex, dendritic spines, mood disorders
- MeSH terms
- Animals, Antidepressive Agents, Depression, Ketamine, Male, Neurons, Neuropeptides, Phenols, Piperidines, Synapses, Time Factors, Protein Biosynthesis, Signal Transduction, Receptors, N-Methyl-D-Aspartate, Rats, Sprague-Dawley, Protein Serine-Threonine Kinases, Sirolimus, Intracellular Signaling Peptides and Proteins, Dendritic Spines, Rats, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.